Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Robert A Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, Luke Coyle, Carlos De Castro, Chieh Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, Henk André Kroon, Russell P. Rother, Peter Hillmen

Research output: Contribution to journalArticle

Abstract

The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations with results from an open-label, non-placebo-controlled, 52-week, phase 3 clinical safety and efficacy study evaluating eculizumab in a broader PNH patient population. Eculizumab was administered by intravenous infusion at 600 mg every 7 ± 2 days for 4 weeks; 900 mg 7 ± 2 days later; followed by 900 mg every 14 ± 2 days for a total treatment period of 52 weeks. Ninety-seven patients at 33 international sites were enrolled. Patients treated with eculizumab responded with an 87% reduction in hemolysis, as measured by lactate dehydrogenase levels (P <.001). Baseline fatigue scores in the FACIT-Fatigue instrument improved by 12.2 ± 1.1 points (P <.001). Eculizumab treatment led to an improvement in anemia. The increase in hemoglobin level occurred despite a reduction in transfusion requirements from a median of 8.0 units of packed red cells per patient before treatment to 0.0 units per patient during the study (P <.001). Overall, transfusions were reduced 52% from a mean of 12.3 to 5.9 units of packed red cells per patient. Forty-nine patients (51%) achieved transfusion independence for the entire 52-week period. Improvements in hemolysis, fatigue, and transfusion requirements with eculizumab were independent of baseline levels of hemolysis and degree of thrombocytopenia. Quality of life measures were also broadly improved with eculizumab treatment. This study demonstrates that the beneficial effects of eculizumab treatment in patients with PNH are applicable to a broader population of PNH patients than previously studied. This trial is registered at http://clinicaltrials.gov as NCT00130000.

Original languageEnglish (US)
Pages (from-to)1840-1847
Number of pages8
JournalBlood
Volume111
Issue number4
DOIs
StatePublished - Feb 15 2008

Fingerprint

Complement Inactivating Agents
Paroxysmal Hemoglobinuria
Hemolysis
Fatigue of materials
Fatigue
Therapeutics
Cells
Patient treatment
eculizumab
L-Lactate Dehydrogenase
Labels

ASJC Scopus subject areas

  • Hematology

Cite this

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. / Brodsky, Robert A; Young, Neal S.; Antonioli, Elisabetta; Risitano, Antonio M.; Schrezenmeier, Hubert; Schubert, Jörg; Gaya, Anna; Coyle, Luke; De Castro, Carlos; Fu, Chieh Lin; Maciejewski, Jaroslaw P.; Bessler, Monica; Kroon, Henk André; Rother, Russell P.; Hillmen, Peter.

In: Blood, Vol. 111, No. 4, 15.02.2008, p. 1840-1847.

Research output: Contribution to journalArticle

Brodsky, RA, Young, NS, Antonioli, E, Risitano, AM, Schrezenmeier, H, Schubert, J, Gaya, A, Coyle, L, De Castro, C, Fu, CL, Maciejewski, JP, Bessler, M, Kroon, HA, Rother, RP & Hillmen, P 2008, 'Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria', Blood, vol. 111, no. 4, pp. 1840-1847. https://doi.org/10.1182/blood-2007-06-094136
Brodsky, Robert A ; Young, Neal S. ; Antonioli, Elisabetta ; Risitano, Antonio M. ; Schrezenmeier, Hubert ; Schubert, Jörg ; Gaya, Anna ; Coyle, Luke ; De Castro, Carlos ; Fu, Chieh Lin ; Maciejewski, Jaroslaw P. ; Bessler, Monica ; Kroon, Henk André ; Rother, Russell P. ; Hillmen, Peter. / Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. In: Blood. 2008 ; Vol. 111, No. 4. pp. 1840-1847.
@article{b11c1b68449a4eeca890ac66cfb7b18d,
title = "Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria",
abstract = "The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations with results from an open-label, non-placebo-controlled, 52-week, phase 3 clinical safety and efficacy study evaluating eculizumab in a broader PNH patient population. Eculizumab was administered by intravenous infusion at 600 mg every 7 ± 2 days for 4 weeks; 900 mg 7 ± 2 days later; followed by 900 mg every 14 ± 2 days for a total treatment period of 52 weeks. Ninety-seven patients at 33 international sites were enrolled. Patients treated with eculizumab responded with an 87{\%} reduction in hemolysis, as measured by lactate dehydrogenase levels (P <.001). Baseline fatigue scores in the FACIT-Fatigue instrument improved by 12.2 ± 1.1 points (P <.001). Eculizumab treatment led to an improvement in anemia. The increase in hemoglobin level occurred despite a reduction in transfusion requirements from a median of 8.0 units of packed red cells per patient before treatment to 0.0 units per patient during the study (P <.001). Overall, transfusions were reduced 52{\%} from a mean of 12.3 to 5.9 units of packed red cells per patient. Forty-nine patients (51{\%}) achieved transfusion independence for the entire 52-week period. Improvements in hemolysis, fatigue, and transfusion requirements with eculizumab were independent of baseline levels of hemolysis and degree of thrombocytopenia. Quality of life measures were also broadly improved with eculizumab treatment. This study demonstrates that the beneficial effects of eculizumab treatment in patients with PNH are applicable to a broader population of PNH patients than previously studied. This trial is registered at http://clinicaltrials.gov as NCT00130000.",
author = "Brodsky, {Robert A} and Young, {Neal S.} and Elisabetta Antonioli and Risitano, {Antonio M.} and Hubert Schrezenmeier and J{\"o}rg Schubert and Anna Gaya and Luke Coyle and {De Castro}, Carlos and Fu, {Chieh Lin} and Maciejewski, {Jaroslaw P.} and Monica Bessler and Kroon, {Henk Andr{\'e}} and Rother, {Russell P.} and Peter Hillmen",
year = "2008",
month = "2",
day = "15",
doi = "10.1182/blood-2007-06-094136",
language = "English (US)",
volume = "111",
pages = "1840--1847",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

AU - Brodsky, Robert A

AU - Young, Neal S.

AU - Antonioli, Elisabetta

AU - Risitano, Antonio M.

AU - Schrezenmeier, Hubert

AU - Schubert, Jörg

AU - Gaya, Anna

AU - Coyle, Luke

AU - De Castro, Carlos

AU - Fu, Chieh Lin

AU - Maciejewski, Jaroslaw P.

AU - Bessler, Monica

AU - Kroon, Henk André

AU - Rother, Russell P.

AU - Hillmen, Peter

PY - 2008/2/15

Y1 - 2008/2/15

N2 - The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations with results from an open-label, non-placebo-controlled, 52-week, phase 3 clinical safety and efficacy study evaluating eculizumab in a broader PNH patient population. Eculizumab was administered by intravenous infusion at 600 mg every 7 ± 2 days for 4 weeks; 900 mg 7 ± 2 days later; followed by 900 mg every 14 ± 2 days for a total treatment period of 52 weeks. Ninety-seven patients at 33 international sites were enrolled. Patients treated with eculizumab responded with an 87% reduction in hemolysis, as measured by lactate dehydrogenase levels (P <.001). Baseline fatigue scores in the FACIT-Fatigue instrument improved by 12.2 ± 1.1 points (P <.001). Eculizumab treatment led to an improvement in anemia. The increase in hemoglobin level occurred despite a reduction in transfusion requirements from a median of 8.0 units of packed red cells per patient before treatment to 0.0 units per patient during the study (P <.001). Overall, transfusions were reduced 52% from a mean of 12.3 to 5.9 units of packed red cells per patient. Forty-nine patients (51%) achieved transfusion independence for the entire 52-week period. Improvements in hemolysis, fatigue, and transfusion requirements with eculizumab were independent of baseline levels of hemolysis and degree of thrombocytopenia. Quality of life measures were also broadly improved with eculizumab treatment. This study demonstrates that the beneficial effects of eculizumab treatment in patients with PNH are applicable to a broader population of PNH patients than previously studied. This trial is registered at http://clinicaltrials.gov as NCT00130000.

AB - The terminal complement inhibitor eculizumab was recently shown to be effective and well tolerated in patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, we extended these observations with results from an open-label, non-placebo-controlled, 52-week, phase 3 clinical safety and efficacy study evaluating eculizumab in a broader PNH patient population. Eculizumab was administered by intravenous infusion at 600 mg every 7 ± 2 days for 4 weeks; 900 mg 7 ± 2 days later; followed by 900 mg every 14 ± 2 days for a total treatment period of 52 weeks. Ninety-seven patients at 33 international sites were enrolled. Patients treated with eculizumab responded with an 87% reduction in hemolysis, as measured by lactate dehydrogenase levels (P <.001). Baseline fatigue scores in the FACIT-Fatigue instrument improved by 12.2 ± 1.1 points (P <.001). Eculizumab treatment led to an improvement in anemia. The increase in hemoglobin level occurred despite a reduction in transfusion requirements from a median of 8.0 units of packed red cells per patient before treatment to 0.0 units per patient during the study (P <.001). Overall, transfusions were reduced 52% from a mean of 12.3 to 5.9 units of packed red cells per patient. Forty-nine patients (51%) achieved transfusion independence for the entire 52-week period. Improvements in hemolysis, fatigue, and transfusion requirements with eculizumab were independent of baseline levels of hemolysis and degree of thrombocytopenia. Quality of life measures were also broadly improved with eculizumab treatment. This study demonstrates that the beneficial effects of eculizumab treatment in patients with PNH are applicable to a broader population of PNH patients than previously studied. This trial is registered at http://clinicaltrials.gov as NCT00130000.

UR - http://www.scopus.com/inward/record.url?scp=41349089713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41349089713&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-06-094136

DO - 10.1182/blood-2007-06-094136

M3 - Article

C2 - 18055865

AN - SCOPUS:41349089713

VL - 111

SP - 1840

EP - 1847

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -